Categories: News

Aptose to Participate in Two Biotech Events in January 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

H.C. Wainwright BIOCONNECT Virtual Conference —

11th Annual LifeSci Partners Corporate Access Event —

SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced that the company will participate in two separate biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference and the 11th Annual LifeSci Partners Corporate Access Event. The Aptose management team will be hosting investor meetings during both events.

Details of the events are as follows:

Event:     H.C. Wainwright BIOCONNECT Virtual Conference
Date:     January 10-13, 2022
Time:     Presentations available starting at 7:00 a.m., ET on January 10, 2022
Webcast:     Accessible for registered conference attendees via the conference’s virtual platform.
       
Event:     11th Annual LifeSci Partners Corporate Access Event
Date:     January 5-7, 2022
1×1 Meeting
Requests:
    Register and submit 1×1 meeting requests here.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML), and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.  

For further information, please contact:

Aptose Biosciences Inc.     LifeSci Advisors, LLC
Susan Pietropaolo     Dan Ferry, Managing Director
Investor Relations     617-430-7576 
201-923-2049     Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com      

Staff

Recent Posts

NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina

NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem  RALEIGH, N.C., June…

1 day ago

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…

2 days ago

Rocketseed launches essential email signature guide for healthcare organizations

New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…

2 days ago

Hospital PMI® at 52%; May 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…

2 days ago

Infisical Secures $16M Series A to Redefine Enterprise Secrets, Identity, and Access Management

Open-source leader democratizes enterprise-grade secrets management for fastest-growing startups, Fortune 500 enterprises, and nation-states. SAN…

2 days ago

Choctaw Nation and Healthy Together Launch Streamlined Summer EBT Program in Just Six Weeks

MIAMI, June 6, 2025 /PRNewswire/ -- Healthy Together, a leading provider of health and human…

2 days ago